Want to see PYPD full AI Analyst Report?
PYPD Stock Chart & Stats
$4.74
-$0.21(-6.71%)
At close: 4:00 PM EST
$4.74
-$0.21(-6.71%)
Day’s Range― - ―
52-Week Range$3.06 - $5.62
Previous CloseN/A
Volume10.68K
Average Volume (3M)72.46K
Market Cap
$103.43M
Enterprise Value$39.73M
Total Cash (Recent Filing)$11.10M
Total Debt (Recent Filing)$2.34M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 12, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding19,083,237
10 Day Avg. Volume44,210
30 Day Avg. Volume72,461
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)6.47
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$11.00Price Target Upside132.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.
Financing And Cash RunwayThe successful financing extends operational runway, providing financial stability to advance clinical trials and regulatory activities.
Market Potential For D-PLEX100The large addressable market for D-PLEX100 in surgical procedures offers significant revenue potential upon successful commercialization and approval.
Bears Say
Consistent Financial LossesOngoing financial losses highlight challenges in achieving profitability, which could impact long-term sustainability and require continued external financing.
Negative EquityNegative equity suggests solvency issues, limiting financial flexibility and increasing reliance on external funding to support operations.
Increased R&D ExpensesRising R&D costs, while necessary for product development, exacerbate financial strain and may delay the path to profitability if not managed effectively.
PolyPid News
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $3.06 and its highest was $5.62 in the past 12 months.
What is PolyPid Ltd.’s market cap?
PolyPid Ltd.’s market cap is $103.43M.
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on May 13, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.083.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -0.37.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 19,083,237 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -7.456%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Currently, no hedge funds are holding shares in PYPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PolyPid Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (132.07% Upside)
$11.00 (132.07% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.90%
12-Months-Change
Fundamentals
Return on Equity
-241.96%
Trailing 12-Months
Asset Growth
13.72%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
PYPD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial forward momentum: a rolling NDA is underway with Fast Track/Breakthrough designations, strong SHIELD II efficacy and ~30-day PK data, manufacturing and inspection preparedness, late-stage U.S. partnership discussions, progress on a planned EU MAA, and elimination of outstanding loan liabilities. Major risks highlighted include a limited cash runway into H2 2026, the NDA not yet fully complete or accepted, dependence on a not-yet-finalized commercial partner, and uncertainty around FDA inspection timing (partly due to geopolitical factors). Overall, the company presented multiple near-term value-driving milestones balanced by execution and funding risks.View all PYPD earnings summariesPYPD Stock 12 Month Forecast
Average Price Target
$11.00
▲(132.07% Upside)
Technical Analysis
Citius Pharmaceuticals
―
SAB Biotherapeutics
―
Liminatus Pharma
―
Tao Synergies
―
Apollomics
―
Ownership Overview
―
Insiders
―
Mutual Funds
14.64% Other Institutional Investors
85.36% Public Companies and
Individual Investors